Summary
Alpha- and gamma-interferons have been shown to actively suppress hematopoiesis in patients in the chronic phase of chronic myelogenous leukemia in vitro and in vivo. Since both interferons act through different receptors on their hematopoietic target cells, they are expected to be capable of independently inhibiting abnormal blood cell development in patients with chronic myelogenous leukemia. We have utilized recombinant human interferon alfa-2c to treate 11 patients with Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase, who were resistant to previous interferon gamma therapy. Ten of the patients were evaluable for hematologic, cytogenetic and molecular-genetic response following interferon alfa-2c therapy for 6 to 30 months. In 5 patients, IFN alfa-2c treatment failed due to lack of hematologic response. A complete hematologic or partial hematologic response was achieved in the remaining 5 patients. Three of these experienced cytogenetic improvement with reappearence of 100% diploid hematopoietic cells and disappearence of c-abl/bcr rearrangement in one patient. In two patients interferon alfa-2c did not prevent transformation of the disease into an accelerated state or blast crisis, respectively. We conclude that recombinant human interferon alfa-2c may also control hematopoiesis in interferon-gamma resistant chronic myelogenous leukemia patients, although the long-term response will need to be elucidated in further studies.
Similar content being viewed by others
References
Alimena G, Morra E, Lazzarino M, Liberati AM, Montefusco E, Inverardi D, Bernasconi P, Mancini M, Donti E, Grignani F, Bernasconi C, Dianzani F, Mandelli F (1988) Interferon alfa-2b as therapy for Ph'-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration. Blood 72: 642–647
Bergsagel DE, Haas RH, Messner HA (1987) Interferon alfa-2b in the treatment of chronic granulocytic leukemia. Invest New Drugs 5: 9–18
Branca AA, Baglioni C (1981) Evidence that types I and II Interferons have different receptors. Nature 294: 768–772
Champlin R, Goldman JM, Gale RP (1988) Bone marrow transplantation in chronic myelogenous leukemia. Semin Hematol 25: 74–80
Griffin JD (1986) The management of chronic myelogenous leukemia. Semin Hematol 23: 20–26
Grosveld G, Verwoerd T, Van Agthoven T, de Klein A, Ramanchandran K, Heisterkamp N, Stam K, Groffen J (1986) The chronic myelocytic cell line K562 contains a breakpoint in bcr and produces a chimeric bcr/c-abl transcript. Mol Cell Biol 6: 607–616
Herrmann F, Lindemann A, Otto J, Mertelsmann R (1988) In vivo effects of Interferon-gamma in chronic myelogenous leukemia. In: Huhn D, Hellriegel KP, Niederle N (eds) Chronic myelocytic leukemia and Interferon. Springer, Berlin Heidelberg New York, pp 113–118
Kawasaki ES, Clark SS, Coyne MY, Smith SD, Champlin R, Witte ON, McCormick F (1988) Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemiaspecific mRNA sequences amplified in vitro. Proc Natl Acad Sci USA 89: 5698–5702
Klimpel GR, Fleischmann WR, Klimpel KD (1982) Gamma-Interferon and Interferon alpha/beta suppress murine myeloid colony formation: Magnitude of suppression is dependent upon level of colony-stimulating factor. J Immunol 129: 76–81
Kurzrock R, Talpaz M, Kantarjian H, Walters R, Saks S, Trujillo JM, Gutterman JU (1987) Therapy of chronic myelogenous leukemia with recombinant Interferon-gamma. Blood 70: 943–947
Mandelli F, Tribalto M, Cantonetti M, Petrucci MT, Boccadoro M, Pileri A, Marmont F, Resegotti L, Lauta V, Dammacco F (1988) Recombinant Interferon alfa-2b as post-induction therapy for responding multiple myeloma patients. M 84 protocol. Cancer Treat Rev 15: 43–48
Niederle N, Kloke D, Osieka R, Wandl U, Opalka B, Schmidt CG (1987) Interferon alfa-2b in the treatment of chronic myelogenous leukemia. Semin Oncol 14: 29–35
Queseda JR, Reuben J, Manning JT, Hersh EM, Gutterman JU (1984) Alpha Interferon for induction of remission in hairy cell leukemia. N Engl J Med 310: 15–20
Seabreight M (1971) A rapid banding technique for human chromosomes. Lancet II: 971–974
Sokal JE, Baccarani M, Russo D, Tura S (1988) Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 25: 49–61
Southern E (1975) Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol 98: 503–509
Talpaz M, Mavligit G, Keating M, Walters RS, Gutterman JU (1983) Human leukocyte Interferon to control thrombocytosis in chronic myelogenous leukemia. Ann Intern Med 99: 789–792
Talpaz M, Kantarjian HM, McCredie KB, Trujillo JM, Keating MJ, Gutterman JU (1986) Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med 314: 1065–1069
Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo JM, Gutterman JU (1987) Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 69: 1280–1288
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Herrmann, F., Jonas, D., Helfrich, S.G. et al. Interferon alfa-2c in chronic myelogenous leukemia (CML): Hematologic, cytogenetic and molecular-genetic response of patients with chronic phase CML previously resistant to therapy with interferon gamma. Blut 61, 226–231 (1990). https://doi.org/10.1007/BF01744136
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01744136